Market Research Logo

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

About Human Respiratory Syncytial Virus Drugs

Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.

Technavio’s analysts forecast the global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global human respiratory syncytial virus drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.

The market is divided into the following segments based on geography:

  • Europe
  • ROW
  • US
Technavio's report, Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical
Other prominent vendors
  • Ablynx
  • ADMA Biologics
  • Alnylam Pharmaceuticals
  • Ark Biosciences
  • Aviragen Therapeutics
  • Bavarian Nordic
  • Boehringer Ingelheim
  • Gilead Sciences
  • ImmunoVaccine Technologies
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Medivir
  • Mucosis
  • Mymetics Corporation
  • Novavax
  • Regeneron Pharmaceuticals
  • ReViral
  • Vaxart
Market driver
  • Novel diagnostic tools increase patient population.
  • For a full, detailed list, view our report
Market challenge
  • Continuous change in guidelines from healthcare organizations impacts market growth.
  • For a full, detailed list, view our report
Market trend
  • Emergence of new entrants likely to change market dynamics.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global human respiratory syncytial virus drugs market: AstraZeneca, AbbVie, GSK, and Teva Pharmaceutical.

Other Prominent Vendors in the market are: Ablynx, ADMA Biologics, Alnylam Pharmaceuticals, Ark Biosciences, Aviragen Therapeutics, Bavarian Nordic, Boehringer Ingelheim, Gilead Sciences, ImmunoVaccine Technologies, Johnson & Johnson, Kyowa Hakko Kirin, Medivir, Mucosis, Mymetics, Novavax, Regeneron Pharmaceuticals, ReViral, and Vaxart.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period. For instance, in January 2016, Mucosis received $4.1 million funding from the Wellcome Trust, a global charitable foundation focusing on improving health, to advance SynGEM, its proprietary intranasal RSV vaccine, into phase I and IIa human clinical trials. In September 2015, OrbiMed and Edmond de Rothschild Investment Partners co-led a $21 million series A round in ReViral, a London-based company that is developing RV521, a drug for the treatment of RSV. In June 2015, Immunovaccine commenced phase I clinical study of its DPX-RSV vaccine. The vaccine candidate contains a specific target and a viral protein that is active on the surface of infected cells. It is believed that an immune response to the specific target will limit the severity of RSV infection. The entry of new companies will certainly pave the way for the development of novel products for the treatment of RSV.”

According to the report, one driver in the market is presence of large patient pool fuels market growth. RSV is the leading cause of lower respiratory tract infections in infants and young children. Each year, 4-5 million children younger than four years of age acquire an RSV infection, and more than 0.12 million are hospitalized annually in the US because of this infection. For example, approximately 25 to 40 out of 100 individuals with RSV have signs or symptoms of pneumonia or bronchiolitis. Five to 20 out of 1,000 require hospitalization. Also, adults with compromised immune systems and of ages 65 and older are also at a higher risk of severe disease. In the US, on average, RSV leads to 57,257 hospitalizations among children of ages below 5 years; 2.1 million outpatient visits among children less than 5 years; and 0.17 million hospitalizations and 14,000 death cases among adults of ages more than 65 years. The presence of this large RSV patient pool with highly unmet medical needs with single approved therapy is expected to drive the market growth during the forecast period.

Further, the report states that one challenge in the market is continuous change in guidelines from healthcare organizations impacts market growth. The dynamic nature of guidelines from the American Academy of Pediatrics Committee on Infectious Disease (AAPCID) restricted the patients eligible for preventive treatment with Synagis, the leading drug in the market. Synagis received US FDA approval in June 1998 for the treatment of lower respiratory infection caused by RSV. Since then, the AAPCID updated its guidance related to Synagis four times. The recent update (2014) states that the use of Synagis prophylaxis in infants and children should be restricted to those that are at increased risk of RSV infection. Earlier, the definition of high-risk children on the Synagis package was not included. Most payers in the US have implemented these guidelines in 2014.



Companies Mentioned

Other Prominent Vendors in the market are: Askon Engineers, Bio JetDrier, HOKWANG INDUSTRIES, Taishan Jieda Electrical Industrial, Panasonic, and Palmer Fixture.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Key customer segments of global human respiratory syncytial virus drugs market
  • Disease overview
    • Understanding the disease
      • Table Snapshot of RSV infection
    • Symptoms
    • Causes
    • Risk factors
    • Complications
    • Tests and diagnosis
    • Key buying criteria
      • Table Key buying criteria for RSV drugs
      • Table Factors affecting the adoption rates of RSV drugs
  • Pipeline analysis
    • Table Pipeline analysis of key vendors in global human respiratory syncytial virus drugs market
    • Table Percentage share of drug candidates by stage of development
    • Table Pipeline candidates: Global human respiratory syncytial virus drugs market
  • Market landscape
    • Global respiratory syncytial virus drugs market
      • Table Global human respiratory syncytial virus drugs market snapshot
      • Table Analysis of global human respiratory syncytial drugs market
      • Table Global human respiratory syncytial virus drugs market 2015-2020 ($ billions)
      • Table Emerging vendors and their initiatives
      • Table Opportunity analysis of global respiratory syncytial virus drugs market
      • Table Opportunity analysis in developed and emerging markets
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by category of drug
    • Table Segmentation of global human respiratory syncytial virus drugs market by type of drug 2015
    • Approved Drugs
    • Off-label drugs
  • Geographical segmentation
    • Table Segmentation of global human respiratory syncytial virus drugs market based on geography 2015 and 2020
    • Table Global human respiratory syncytial virus drugs market revenue by geography 2015-2020 ($ millions)
    • Human respiratory syncytial virus drugs market in US
      • Table Incidence of RSV infections in US (on average every year)
      • Table Global human respiratory syncytial virus drugs market in US 2015-2020 ($ millions)
      • Table Key drivers and challenges in US
    • Human respiratory syncytial virus drugs market in Europe
      • Table Human respiratory syncytial virus drugs market in Europe 2015-2020 ($ millions)
      • Table Trends in global human respiratory syncytial drugs market in Europe
    • Human respiratory syncytial virus drugs market in ROW
      • Table Global human respiratory syncytial virus drugs market in ROW 2015-2020 ($ millions)
      • Table Key drivers and challenges in ROW
  • Market drivers
    • Presence of large patient pool fuels market growth
      • Table Trends in RSV epidemics
    • Launch of novel products
      • Table Potential products
    • Novel diagnostic tools increase patient population
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Continuous change in guidelines from healthcare rganizations impacts market growth
      • Table Change in guidelines of AAPCID and its consequences
    • Cyclical nature of market hinders growth opportunities
      • Table Impact of cyclical nature of RSV epidemics
    • Limited drugs in market leading to low penetration rates
      • Table Factors affecting penetration rates
      • Table Forcefield analysis of drivers and challenges in global human respiratory syncytial virus drugs market
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Emergence of new entrants likely to change market dynamics
      • Table Potential entrants
    • Growing strategic collaborations fostering innovation
      • Table Strategic alliances
    • Active participation from emerging economies toward R&D
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global human respiratory syncytial virus drugs market 2015
      • Table Market share analysis 2015
      • Table Market penetration of various RSV drug manufacturers in global human respiratory syncytial virus drugs market (2015)
      • Table Strategic success factors of companies in global human respiratory syncytial virus drugs market
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: Key highlights
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
      • Table AstraZeneca: Revenue of Synagis 2013-2015 ($ billions)
      • Table AstraZeneca: Geographic segmentation of Synagis 2015
    • AbbVie
      • Table AbbVie: Strength assessment
      • Table AbbVie: Strategy assessment
      • Table AbbVie: Opportunity assessment
      • Table AbbVie: Revenue of Synagis 2013-2015 ($ millions)
    • GSK
      • Table GSK: Profile
      • Table GSK: Strength assessment
      • Table GSK: Strategy assessment
      • Table GSK: Opportunity assessment
      • Table GSK: Revenue of Ventolin 2013-2015 ($ billions)
      • Table GSK: Geographical segmentation of Ventolin 2015
    • Teva Pharmaceutical
      • Table Teva Pharmaceutical: Profile
      • Table Teva Pharmaceutical: Strength assessment
      • Table Teva Pharmaceutical strategy assessment
      • Table Teva Pharmaceutical: Opportunity assessment
      • Table Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report